Loading company…
NVision develops quantum technology for medical imaging and therapy monitoring.
Founded in 2015 and based in Ulm, Germany, NVision develops hyperpolarization technology for MRI to support early diagnosis and assessment of treatment response. Its technology uses parahydrogen-induced polarization to evaluate metabolism in people and animals. In May 2026, it raised USD 38 million in Series B funding from Abbott Capital Management, Matterwave Ventures Management, b2venture, CDP Venture Capital, Entree Capital, and Playground Ventures, as part of a larger USD 55 million Series B and venture debt round.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in